A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
Clinical trial NCT07609719 · RECRUITING
Trial details
- NCT number
- NCT07609719
- Sponsor
- Genentech, Inc.
- Status
- RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-17
- Primary completion
- 2029-02-28
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.